Drug intelligence / Profile preview

SARS-CoV-2 variants mRNA vaccine

Development stage: Phase 3
Lead developer: The First Affiliated Hospital of Guangzhou Medical University
Modality: Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intramuscular, Transdermal, Intranasal, Inhalation, Intratracheal, Subcutaneous, Intradermal

Overview

The SARS-CoV-2 variants mRNA vaccine is an mRNA-based vaccine designed to target SARS-CoV-2 variants. It specifically utilizes a chimera S protein (Spike protein) to elicit an immune response. This vaccine is currently undergoing clinical trials for the prevention of Novel Coronavirus Pneumonia (COVID-19). It is being developed by companies including Yunnan Walvax Biotechnology Co., Ltd. and The First Affiliated Hospital of Guangzhou Medical University.

Other names: chimera S protein vaccine新型冠状病毒变异株mRNA疫苗（S蛋白嵌合体）

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on SARS-CoV-2 variants mRNA vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SARS-CoV-2 variants mRNA vaccine.